

## Antimicrobial Use and Resistance (AUR): Pharmacy Data Monthly Electronic Upload Specification Tables

These data will be collected in an aggregate monthly electronic file transfer from the facility to NHSN via Clinical Document Architecture (CDA).

Table 1. CDA	ile Descripto	rs These da	ta elements will b	e transmitted with eac	h month's report.		
Variable Name Description of Variable							
Facility OID	NHSN F	acility ID number					
Application OID	) Vendor	software ID numbe	er				
SDS validation ID ID provided by NHSN Tea			m confirming ve	endor software pass	sed validation		
location	NHSN lo	ocation code					
month Denominator month							
year	Denomi	nator year					
Table 2. Aggre	gate Patient I	Information	These data eler month.	ments are aggregated	to the location and	facility wide inpatie	nt level for each
		ion of Variable	monur.				
numDaysPresent Total number of days present							
numTherapyDa	······	of therapy days					
numAdmissions Number of admissions							
		cy Information	record (eMA location and	elements are obtained AR) or bar coding med I facility wide inpatient	ication administrat	ion (BCMA) and ago	on administration gregated to the
Variable Name		ion of Variable		Examples			
drugIngredient		robial ingredient		(see Table 3a)  Digestive tract, respiratory tract, intravenous route, intramuscular route			
routeDrugAdmi	n Roule o	f administration		Digestive tract, respirat ist of antimicrobials cui			
Table 3a. List	of Antimicrob	ials Accepted	use reportin		Terniy accepted in	to Wilow as part of	une anumierobia
Amantadine	Aztreonam	Cefoxitin	Clarithromycin	Fidaxomicin	Meropenem	Oseltamivir	Rimantadine
Amikacin	Baloxavir marboxil	Cefpodoxime	Clindamycin	Fluconazole	Meropenem/ Vaborbactam	Oxacillin	Sulfamethoxa zole/ Trimethoprim
Amikacin Liposomal	Caspofungin	Cefprozil	Colistimethate	Fosfomycin	Metronidazole	Penicillin G	Tedizolid
Amoxicillin	Cefaclor	Ceftaroline	Colistin	Gemifloxacin	Micafungin	Penicillin V	Telavancin
Amoxicillin/ Clavulanate	Cefadroxil	Ceftazidime	Dalbavancin	Gentamicin	Minocycline	Peramivir	Tetracycline
Amphotericin B	Cefazolin	Ceftazidime/ Avibactam	Daptomycin	Imipenem/ Cilastatin	Molnupiravir	Piperacillin/ Tazobactam	Tigecycline
Amphotericin B lipid complex	Cefdinir	Ceftolozane/ Tazobactam	Delafloxacin	Imipenem/ Cilastatin/ Relebactam	Moxifloxacin	Plazomicin	Tinidazole
Amphotericin B liposomal	Cefepime	Ceftriaxone	Dicloxacillin	Isavuconazonium	Nafcillin	Polymyxin B	Tobramycin
Ampicillin	Cefiderocol	Cefuroxime	Doxycycline	Itraconazole	Nirmatrelvir	Posaconazole	Vancomycin
Ampicillin/ Sulbactam	Cefixime	Cephalexin	Eravacycline	Lefamulin	Nitrofurantoin	Quinupristin/ Dalfopristin	Voriconazole
Anidulafungin	Cefotaxime	Chloramphenicol	Ertapenem	Levofloxacin	Omadacycline	Remdesivir	Zanamivir
Azithromycin	Cefotetan	Ciprofloxacin	Erythromycin	Linezolid	Oritavancin	Rifampin	
Assurance of Co	nfidentiality: The	e voluntarily provided	information obtain	ed in this surveillance sy	stem that would pe	ermit identification of a	any individual or

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

Public reporting burden of this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333 ATTN: PRA (0920-0666).